NCT06197802View on ClinicalTrials.gov

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

Active, not recruitingOBSERVATIONAL
Enrollment

392

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

April 5, 2024

Study Completion Date

September 1, 2025

Conditions
Cervical CancerCondylomata Acuminata
Interventions
BIOLOGICAL

Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)

Three doses administered intramuscularly at 0, 45 day and 6 month.

BIOLOGICAL

Gardasil®9

Three doses administered intramuscularly at 0, 45 day and 6 month.

Trial Locations (1)

210009

Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing

All Listed Sponsors
collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

lead

Xiamen University

OTHER